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1. Introduction 
A growing body of clinical and experimental evidence has revealed a strong impact of drug 
resistance on clinical outcomes, especially in cancer therapy, since carcinogenesis is a multi-
step, multi-pathway and multi-focal process, which involves a series of epigenetic and ge-
netic alterations [1-3]. In order to solve the serious issue facing clinical treatment, combina-
tion therapy is now widely advocated for clinical use and has been shown to have a benefi-
cial effect on patient satisfaction [3, 4]. For instance, 5-fluorouracil (5-FU) and leucovorin 
with either irinotecan or oxaliplatin have been widely used for the treatment of patients 
with colorectal cancer [5, 6]. Furthermore, recently, various types of molecular target-based 
drugs, such as cetuximab and bevacizumab, are being used clinically. Although these con-
tinuous efforts to exploit potential combination therapies are ongoing, there is still a grow-
ing concern about treatment resistance, disease relapse and side effects of drugs clinically 
used. Of note, numerous components of edible plants, collectively termed phytochemicals 
that have beneficial effects for health, are increasingly being reported in the scientific litera-
ture and these compounds are now widely recognized as potential therapeutic compounds 
[1, 2, 4, 7, 8]. In fact, natural product derived substances, especially polyphenolic com-
pounds with very little toxic effects on normal cells, have attracted great attention in the 
therapeutic arsenal in clinical oncology due to their chemopreventive, antitumoral, radio-
sensibilizing and chemosensibilizing activities against various types of aggressive and re-
current cancers [1, 8-10].   
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Apoptosis, or programmed cell death, plays a key role in the development and growth 
regulation of normal cells, and is often dysregulated in cancer cells [11, 12]. It has been 
accepted that the aim of anticancer therapy is generally focused on apoptosis induction in 
premalignant and malignant cells, although other multiple molecular mechanisms such as 
modulation of carcinogen metabolism, anti-angiogenesis and induction of differentiation are 
also known to be implicated in its anticancer activity [4, 13]. So far, two principal signal 
pathways of apoptosis have been identified [11, 12]. The intrinsic mechanism of apoptosis 
involves a mitochondrial pathway. Apoptosis stimuli destruct mitochondrial membrane 
structure under the control of Bcl-2 (B-cell leukemia/lymphoma) family, resulting in the 
release of mitochondrial proteins including cytochrome c. Once cytochrome c is released it 
activates caspase-9 (initiator caspase) through the interaction with Apaf-1 (apoptotic 
protease activating factor-1) and dATP [14, 15], which ultimately leads to caspase-3 and -7 
(effector caspases) activation [16]. On the other hand, the extrinsic pathway induced by 
death receptors, such as tumor necrosis factor receptor (TNFR) and Fas, is responsible for 
the activation of caspase-8 and caspase-10 (initiator caspase) accompanied by the activation 
of caspase-3 and -7 [16]. The effector caspases are the final mediators in the intrinsic and 
extrinsic pathways that cleave substrates and lead to cell death. Moreover, a third pathway 
involving endoplasmic reticulum (ER) stress and caspase-12 has been reported to be 
associated in apoptosis [4, 13]. A number of markers have been utilized to reveal apoptosis 
status including cell viability, cytochrome c release, caspase-3 activation, poly (ADP-ribose) 
polymerase (PARP) cleavage, and DNA fragmentation [17].  
Reactive oxygen species (ROS) have been widely believed to play a pivotal role in a wide 
variety of cellular functions, including cell proliferation and differentiation [3, 11]. Further-
more, oxidative stress, as a result of alterations of redox homeostasis due to an imbalance 
between ROS production and elimination, is known to be involved in many diseases such as 
hypoxic injury [11, 18]. Therefore, maintaining ROS homeostasis is crucial for normal cell 
growth and survival. Generally, cancer cells appear to generate more ROS than do normal 
cells due to its increased aerobic glycolysis. Furthermore, cancer cells exhibit increased ROS 
production and altered redox status. Recent studies suggest that these biochemical charac-
teristics of cancer cells can be exploited for therapeutic benefits [3, 18]. Especially, tumors in 
advanced stage frequently exhibit multiple genetic alterations and high oxidative stress, 
suggesting that it is possible to preferentially eliminate these cells by pharmacological ROS 
insults. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxida-
tive stress in cancer cells can confer drug resistance [3, 18]. Thus, abrogation of such drug-
resistant mechanisms by redox modulation could have significant therapeutic implications 
[2, 3, 18, 19]. Indeed, it has been known that altered redox status is closely associated with 
apoptosis induction in various cancer cells [2, 3, 18, 19]. Collectively, manipulating ROS 
levels by redox modulation is a way to selectively kill cancer cells without causing signifi-
cant toxicity to normal cells. 
Polyphenolic compounds such as flavonoids and curcumin have been shown to induce 
apoptosis in various malignant cells including solid tumors and hematologic malignant cells 
[1, 2, 7-9, 20-22]. Interestingly, the mechanisms underlying the apoptosis induction, 
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associated with their antitumoral, chemopreventive and chemotherapeutic activities, have 
been shown to be implicated in alteration of redox status, since polyphenolic compounds 
are well known to possess both antioxidant and prooxidant activity [1, 2, 7, 8, 10, 20, 22-26].      
In this chapter, we will highlight the recent advances on the cancer preventative activities of 
the polyphenolic compounds, including flavonoids such as anthocyanins, and Vitex agnus-
castus fruit extract (Vitex) in which flavonoids are one of major components, as well as 
curcumin based on the most recent results from in vitro cell culture and in vivo animal 
model tumor systems. We will further summarize the detailed mechanisms underlying their 
cytocidal effects focusing on apoptosis induction. We will also provide detailed insight into 
potential future clinical application of these promising candidates endowed with potent 
antitumor activities, alone or in combination with other anticancer clinical drugs based on 
preclinical and clinical trial results.  
2. Cancer preventative activities of the polyphenolic compounds, 
anthocyanins, Vitex, and curcumin 
2.1. Resource and chemistry of anthocyanins, Vitex, and curcumin    
The most abundant flavonoid constituents of fruits and vegetables are anthocyans (i.e. 
anthocyanins (glycosides), and their aglycones, anthocyanidins) that confer bright red or 
blue coloration on berries and other fruits and vegetables [8, 20]. Anthocyanins are 
especially interesting with respect to other flavonoids because they occur in the diet at 
relatively high concentrations. The daily intake of anthocyanins in the US diet has been 
suggested to be 180-255 mg/day, in contrast, the daily intake of most other dietary 
flavonoids, including genistein, quercetin and apigenin, is estimated to be only 20-25 
mg/day [27]. Anthocyanidins are a diphenylpropane-based polyphenolic ring structure, and 
are limited to a few structure variants including cyanidin, delphinidin, malvidin, 
pelargonidin, peonidin and petunidin (Figure 1), with a distribution in nature of 50%, 12%, 
12%, 12%, 7%, and 7%, respectively, and they present almost exclusively as glycosides, 
anthocyanins [28]. Furthermore, epidemiological evidence has demonstrated that 
consumption of fruits and berries has been associated with decreased risk of developing 
cancer [29]. 
Vitex agnus-castus is a shrub of the Verbenaceae family and is found naturally in the Middle 
East and Southern Europe. Ripe fruit of Vitex agnus-castus has been used as a folk medicine 
for the treatment of various obstetric and gynecological disorders in Europe [30, 31]. 
Itokawa and colleagues have reported that Vitex (an extract from dried ripe Vitex agnus-
castus) possesses cytocidal effects on P388, a mouse leukemia cells, suggesting its antitumor 
activity, and that flavonoids such as luteolin (Figure 2) are one of its major constituents  
[32, 33].  
Curcumin, a hydrophobic polyphenol, also known as turmeric, is a major bioactive 
ingredient extracted from the rhizome of the plant Curcuma longa [34, 35]. Curcumin has 
been used as a dietary supplement as well as therapeutic agent in Chinese medicine and 
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Figure 1. Chemical structure of anthocyanidins 
 
Figure 2. Chemical structure of luteolin 
 
Figure 3. Chemical structures of naturally occurring curcumin. The scheme shows the diketone and 
keto-enol forms of curcumin. Curcumin exists as an equilibrium mixture of two tautomeric forms in 
solution. The enol structure of curcumin, which is stabilized by intramolecular H-bonding, is the most 
energetically stabilized and favored form. 
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other Asian medicines for centuries due to its safety and tolerance [34, 35]. Curcumin has a 
unique conjugated structure including two methylated phenols linked by the enol form of a 
heptadiene-3,5-diketone that gives the compound a bright yellow color (Figure 3) [7, 35]. 
2.2. Involvement of altered redox status in apoptosis induction triggered by 
polyphenolic compounds 
2.2.1. Anthocyans 
It has been demonstrated that anthocyanin-rich extracts from berries and grapes, and sever-
al pure anthocyanins and anthocyanidins, exhibit pro-apoptotic effects in multiple cell types 
such as colon [23, 36], breast [37, 38], prostate [39, 40], and leukemia cancer cells [10, 41]. 
They induce apoptosis through both intrinsic (mitochondrial) and extrinsic (Fas) pathways. 
In the intrinsic pathway, the treatment of cancer cells with anthocyanin results in destabili-
zation of the mitochondrial membrane, cytochrome c release and activation of caspase-9, 
and -3 as well as pro-apoptotic protein such as apoptosis inducing factor [10, 37, 40]. In the 
extrinsic pathway, anthocyanins modulate the expression of Fas and FasL (Fas ligand) in 
cancer cells, which result in the activation of caspase-8, then cleaves Bid to tBid, and ulti-
mately stimulates cytochrome c release [41]. Of note, several lines of evidence have indicat-
ed that oxidative stress resulted from stimulation of ROS production and/or insufficient 
ROS elimination is implicated in anthocyanins-triggered apoptosis induction in cancer cells, 
although broad biological activities including antimutagenesis and anticarcinogenesis of 
anthocyanins are generally attributed to their antioxidant activity [2, 7, 10, 22-25]. Indeed, it 
has been demonstrated that the most common type of anthocyanins, cyanidin-3-rutinoside, 
induced apoptosis in a human myeloid leukemia cell line, HL-60, in a dose- and time-
dependent manner accompanied by accumulation of peroxides [10]. Cyanidin-3-rutinoside 
treatment resulted in ROS-dependent activation of p38 mitogen-activated protein kinase 
(MAPK) and c-Jun N-terminal kinase (JNK), which contributed to cell death by activating 
the mitochondrial pathway mediated by Bim, one of proapoptotic gene of Bcl-2 family [10]. 
More importantly, cyanidin-3-rutinoside treatment did not lead to increased ROS accumula-
tion in normal human peripheral blood mononuclear cells (PBMNC) without inducing cyto-
toxic effects on these cells [10] as indicated by our preliminary data concerning treatment of 
HL-60 and PBMNC with anthocyanidin (unpublished data). These results suggest that cya-
nidin-3-rutinoside could be used in leukemia therapy with the advantages of being widely 
available and selective against tumors. More recently, delphinidin and cyanidin were re-
ported to induce apoptosis in a human metastatic colorectal cancer cell line, LoVo and 
LoVo/ADR, a doxorubicin-resistant LoVo, but not in cells originating from a primary tumor 
site, i.e. Caco-2 [23]. Furthermore, LoVo/ADR was more sensitive to anthocyanins than LoVo 
cells [23]. It has been reported that the rate of lactate production is significantly higher in 
LoVo/ADR than in LoVo cells [42]. Therefore, the differences in changes of cellular energy 
metabolism associated with neoplastic transformation has been suggested to contribute the 
differential sensitivities to these anthocyanins [43]. Moreover, ROS accumulation, inhibition 
of glutathione reductase, and depletion of GSH were observed in the apoptosis triggered by 
anthocyanidins in these metastatic colorectal cancer cell lines [23]. These experimental re-
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sults are in good agreement with previous reports on a possible role of flavonoids, as well as 
other phytochemicals, in modulating the glutathione (GSH) antioxidant activity, including 
regulation of intracellular GSH levels through targeting its synthesis, induction of multiple 
resistant protein 1 mediated GSH efflux, or inhibition of glutathione peroxidase enzyme 
activity observed in hematopoietic malignant and solid cancer cells in vitro and in vivo [19, 
24, 44]. Furthermore, an in vitro study showed that anthocyanidins inhibit glutathione re-
ductase (GR) in an oxygen-dependent manner, presumably via the effect of superoxide [45]. 
Therefore, these results suggest that anthocyanidins may be used as sensitizing agents 
through modulating intracellular redox status in various cancer therapy.  
Intriguingly, a good correlation has been found between anthocyanin chemical structure 
and chemoprotective activity. Indeed, several lines of evidence have shown that the 
number of hydroxyl groups on the B-ring of anthocyanidins is associated with the potency 
of prooxidative [45-47], apoptotic induction [48], anti-transformation [49], as well as anti-
oxidative activities [1, 8]. For instance, delphinidin and cyanidin that possess ortho-
dihydroxyphenyl structure on the B-ring, showed stronger apoptotic induction in human 
leukemia cells [48] and inhibitory effect on 12-O-tetradecanoylphorbol-13-acetate (TPA)-
induced cell transformation [49]. Furthermore, a similar trend of structure-activity 
relationship was also observed in the suppression of transcription factors closely associated 
with intracellular redox status, such as activator protein-1 (AP-1), nuclear factor-κB (NF-
κB), and CCAAT/enhancer-binding protein (C/EBPδ) [20, 49, 50]. Structure-activity studies 
also suggested that the potency as inhibitors of epidermal growth factor receptor (EGFR), a 
target of an expanding class of anticancer therapies [51], might be positively correlated 
with the presence of hydroxyl functions in positions 3’ and 5’ of ring B of the 
anthocyanidinos molecule, and inversely with the presence of methoxy groups in these 
positions. All of these findings provide important molecular basis for the antitumor 
properties of anthocyanidins.      
2.2.2. Vitex 
We have been interesting the effects of naturally derived flavonoids on the growth of 
various types of cancer cells. Of those, we have demonstrated that Vitex exhibits cytotoxic 
activities against various types of solid tumor cells, such as KATO-III (a human gastric 
signet ring carcinoma cell line), COLO 201 (a human colon adenocarcinoma cell line), MCF-7 
(a human breast carcinoma cell line) [52]. More interestingly, no apparent cytotoxicity was 
observed in non-tumor cells, such as human uterine cervical canal fibroblast (HCF) and 
human embryo fibroblast (HE-21) when treated with concentrations showing significant 
cytotoxicity in tumor cells, suggesting a selective cytotoxic activity against tumor cells [52]. 
We further demonstrated that Vitex induced apoptosis accompanied by an accumulation of 
intracellular ROS along with the decrease in the levels of intracellular GSH in KATO-III cells 
[22]. At the same time, our experimental data demonstrated a decrease in the amount of Bcl-
2, Bcl-xL and Bid proteins; an increase in Bad protein; activation of caspase-8, -9 and -3; a 
leakage of cytochrome c from mitochondria in the cells [22]. Furthermore, the addition of an 
antioxidant, N-acetyl-L-cysteine (NAC), or exogenous GSH significantly abrogated the  
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effects of Vitex [22]. Together, our results suggest that a crosstalk between intrinsic and 
extrinsic pathway via Bid activation as a result of oxidative stress plays a critical role in 
Vitex-induced apoptosis in KATO-III cells. We also demonstrated that apoptosis induction 
was observed in Vitex-treated COLO 201, concomitantly with a significant increase in heme 
oxygenase-1 (HO-1) gene expression as observed in KATO-III cells [53]. On the other hand, 
unlike KATO-III, apoptosis induction was not abrogated in the presence of antioxidants, 
such as NAC [53]. We further demonstrated that after treatment with Vitex, the upregula-
tion of ER stress-related genes, such as glucose-regulated protein 78 (GRP78) and C/EBP-
homologous protein (CHOP) along with the activation of caspase-9 and -3 were observed in 
COLO 201 [21]. However, an inhibitor for JNK significantly suppressed the apoptosis induc-
tion associated with caspase-3 activation [21]. These results thus suggest that the activation 
of JNK, and caspase-9 and -3 resulted from ER stress contributed to the apoptosis induction 
in Vitex-treated COLO 201 cells. Taken together, it seems that either oxidative stress-
dependent or ER stress-dependent apoptosis would be triggered in cancer cells treated with 
Vitex depending on different cell types. Most importantly, our in vivo experimental data 
revealed that the administration of Vitex significantly suppressed tumor growth in COLO 
201 xenograft mice, although more studies must be conducted to understand detailed in 
vivo pharmacological characterization of Vitex treatment [21]. In addition, as shown in Fig-
ure 4, we recently demonstrated a significant dose-dependent cytocidal effect in both a well-
differentiated hepatocellular carcinoma (HCC) cell line, HepG2 and an undifferentiated 
HCC cell line, HLE, although the levels of cytotoxic activities of Vitex varied between two 
cells. Similarly, a significant dose-dependent cytocidal effect was also observed in both cells 
when treated with as high as 20 μg/ml luteolin, one of major constituents of Vitex. However, 
there was a trend to increase cell proliferation in both cells when treated with a relatively 
lower concentration of luteolin. On the other hand, 5-FU induced a dose-dependent cyto-
cidal effect on HLE, but not in HepG2. These results indicated that while the cytocidal effect 
of 5-FU was more selective against undifferentiated hepatocellular carcinoma HLE, Vitex 
and luteolin exhibited significant cytocidal effects on both well-differentiated and undiffer-
entiated hepatocellular carcinoma cells, suggesting a possible broad usefulness of these 
compounds to hepatocellular carcinoma therapy. Of note, Vitex has been used to treat pa-
tients with various obstetric and gynecological disorders in Europe [30, 31]. Moreover, it is 
interesting to note that Vitexins, which are isolated from the seed of Chinese herb Vitex 
Negundo and bear a basic flavonoid structure, show cytotoxic and antitumor effects against 
breast, prostate and ovarian cancer cells through apoptosis induction via an intrinsic path-
way based on in vitro and in vivo xenograft tumor models [54]. Therefore, our results pro-
vide a new insight into the clinical use of Vitex for colon cancer and hepatocellular carcino-
ma besides those cancers mentioned above.  
2.2.3. Curcumin 
Curcumin has emerged worldwide as a potent therapeutic substance for treating diverse 
human diseases including various types of cancer, such as leukemia, colon cancer and pan-
creatic cancer [7, 25, 35, 55, 56]. Although the precise mode of action of this compound is  
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Figure 4. Cytocidal effects of Vitex, luteolin and 5-FU on HepG2 and HLE cells. Hepatocellular carci-
noma (HCC) cell lines, HepG2 (well-differentiated) and HLE (undifferentiated) were kindly provided 
by Dr. Yamato Kikkawa (Laboratory of Clinical Biochemistry, School of Pharmacy, Tokyo University of 
Pharmacy and Life Sciences, Tokyo, Japan). After treatment with Vitex (final concentrations: 1, 10, 50 
and 100 μg/ml), luteolin (final concentrations: 0.1, 1, 10 and 20 μg/ml) or 5-FU (1, 10 and 100 μM) for 48 
h, cell viability was determined by XTT dye-reduction assay according to the method described previ-
ously [53]. Significant differences between treatment group and control (*: p<0.05; §: p<0.01; †: p<0.001) 
not yet elucidated, studies have shown that chemopreventive action of curcumin might be 
due to its ability to induce apoptosis through multiple signaling pathways, including 
intrinsic and extrinsic pathways as well as ER stress pathway [7, 57]. It has been suggested 
that curcumin-induced apoptosis is associated with ROS production and/or oxidative stress 
in cancer cells, in spite of its normal antioxidant capacity [7, 57]. Indeed, it has been 
demonstrated that curcumin can generate ROS as a prooxidant in the presence of copper in 
HL-60 cells, resulting in DNA damages and apoptotic cell death [58]. Furthermore, the 
prooxidant action of curcumin may be related to the conjugated β-diketone structure of this 
compound [58]. Kuo et al. also demonstrated that curcumin induced a dose- and time-
dependent apoptotic cell death in the same cells, concomitant with a decrease of Bcl-2 
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expression [59]. However, the antioxidants, NAC, L-ascorbic acid, alpha-tocopherol, catalase 
and superoxide dismutase, all effectively prevented curcumin-induced apoptosis, 
suggesting that curcumin-mediated apoptosis was closely related to the increase in 
intracellular ROS [59]. Besides hematopoietic cancer cells, curcumin-mediated apoptosis in 
human breast epithelial cells (H-ras MCF10A) involved generation of ROS as well as down-
regulation of Bcl-2 and up-regulation of Bax, suggesting redox signaling as a mechanism 
responsible for curcumin-induced apoptosis in these cells [60]. Syng-Ai et al. also 
demonstrated that curcumin-induced apoptosis in human breast tumor cell lines (MCF-7, 
MDAMB) and HepG2 cells is also mediated through the generation of ROS, and that 
depletion of glutathione by buthionine sulfoximine (BSO) promoted the increased 
generation of ROS, thereby further sensitizing the cells to curcumin [61]. Interestingly, 
curcumin had no cytocidal effect on normal rat hepatocytes, because of no superoxide 
generation [61]. These observations suggest that curcumin with broad biological actions 
could be developed into an effective chemopreventive and chemotherapeutic agent based 
on its ability to modulate intracellular redox status. However, the use of curcumin as a 
therapeutic agent has met with considerable skepticism, since as much as 75% of curcumin 
is excreted in the feces [62] and also undergoes repaid inactivation by glucuronidation [63], 
similar to metabolisms of flavonoids [2]. Recently, in order to increase its metabolic stability, 
numerous approaches have been undertaken, such as generating the fluoro-analog of 
curcumin termed Diflourinated-Curcumin (referred to as CDF) that exhibits increased 
metabolic stability [64, 65]. Furthermore, the CDF has been found to exhibit superior growth 
inhibitory properties against cancer cells to the parental compound curcumin [56, 64, 65]. 
3. Potential future application of polyphenolic compounds, alone or in 
combination with, anticancer drugs 
As mentioned in the previous section, the deregulation and sustained activation of multiple 
tumorigenic pathways are typically implicated in cancer development and progression with 
locally advanced and aggressive nature. Consequently, the use of therapeutic agents acting 
on different deregulated gene products, alone or in combination therapy, may represent a 
potentially better strategy than the targeting on one specific oncogenic product to overcome 
treatment resistance and prevent cancer development and disease recurrence [2-4, 7]. So far, 
one of the most successful models for combinatory cancer therapies is all-trans retinoic acid 
(ATRA)/arsenic trioxide (ATO, arsenite) combination as a synergistic therapy for acute 
promyelocytic leukemia (APL) patients, in which ATRA synergizes ATO activity to provide 
a superior efficacy of combination therapy in patient through promoting the effects of ATO 
on several signaling pathway, such as apoptosis induction, differentiation as well as the 
degradation of PML-RARα [a fusion gene between promyelocytic leukemia (PML) gene and 
retinoic acid receptor (RAR) α], a causative gene for APL [4, 13]. In order to understand the 
mode of action of ATO and provide an effective treatment protocol for individual APL 
patients, we recently conducted studies on the pharmacokinetics of ATO in APL patients 
using biological samples such as peripheral blood (PB) and cerebrospinal fluid, and 
demonstrated that not only inorganic arsenic but also methylated arsenic metabolites 
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accumulated in red blood cells during the consecutive administration of ATO to APL 
patients [66]. Furthermore, we have demonstrated for the first time that these arsenic 
metabolites also existed in cerebrospinal fluid [67], in which the concentrations of arsenic 
reached levels necessary for differentiation induction [68, 69]. We further investigated for 
the first time the arsenic speciation in plasma of bone marrow (BM), and demonstrated that 
speciation profiles of BM plasma were very similar to those of PB plasma, suggesting that 
speciation analysis of PB plasma could be predicative for BM speciation [70]. These findings 
on the pharmacokinetics of ATO in APL patients provide a new insight into clinical 
applications of ATO, and may contribute to better therapeutic protocols [4]. Recently, in 
order to understand the clinical side effects of arsenite, we also investigated the effects of 
arsenite on human-derived normal cells, since the clinical side effects of drugs are always 
found as a harmful and undesired effect on normal cells and/or tissues. Based on a study 
using a unique in vitro cell culture system comprising the primary culture chorion and 
amnion cells established in our laboratory [71-73], we demonstrated for the first time that 
transporter genes, such as aquaporin 9 and multidrug resistance associated protein 2 are 
involved in controlling intracellular arsenic accumulation in these primary cultured normal 
cells, which then contribute to differential sensitivity to arsenite cytotoxicity among these 
cells [74].  
The successful clinical efficacy of ATO in the treatment of APL patients has led to 
investigations on exploring potential treatment applications for other malignancies, 
including ATO-resistant hematopoietic cancer and solid tumors [75, 76]. In order to further 
extend our previous study and promote the clinical application of arsenite, we have been 
seeking to explore potential candidate agents, which are expected to not only potentiate the 
efficacy of ATO but also possibly reduce its dosages [4]. In this regard, using HL-60 cells 
which are reported to show resistance to arsenite, we found that delphinidin showed 
selective cytotoxic effects on the cells, but minimal effects on PBMNC, and sensitized the 
cells to arsenite, resulting in the enhancement of arsenite cytotoxicity (Yuan et al. 
manuscript in preparation). Therefore, our experimental data suggest that sensitization of 
HL-60 cells to arsenite achieved by the combination with delphinidin could benefit a 
reduced dosages of arsenite in clinical application, contributing to minimize side effect. The 
clinical trial planning is now underway.  
Of note, it is well known that oxidative stress is involved in the mechanisms underlying 
the therapeutic efficacy of arsenite and plays a major role in the toxicity of arsenite [4, 13, 
77]. In fact, in order to maximally exploit effective ROS-mediated cell death without 
causing significant toxicity to normal cells, redox-based drug combination strategies have 
been proposed [3, 11, 18]. Based on the strategies, ROS-generating reagents including 
natural products derived substances, especially phenolic compounds, have received much 
attention due to their cytocidal effects on tumor cells but little on normal cells. In this 
regard, like the cytocidal effects of cyanidin-3-rutinoside on leukemia cells [10], 
delphinidin 3-sambubioside has also been demonstrated to induce apoptosis in HL-60 
through ROS-mediated mitochondria pathway [78], suggesting these anthocyanins are 
good candidates for ROS-generating reagents, thereby possibly potentiate the action of 
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ATO. Indeed, quercetin and/or genistein are flavonoid with multiple biochemical effects 
such as downregulation of phosphoinositide 3-kinase/Akt signaling pathway and NF-κB 
transcription factor activity [79, 80], tyrosine kinase inhibition [81, 82]. Furthermore, both 
quercetin and genistein have been reported to selectively potentiate ATO-induced 
apoptosis via ROS generation resulted from intracellular GSH depletion, and activation of 
intrinsic and extrinsic apoptotic pathway in human leukemia cell lines such as HL-60, U937 
and THP-1, but not in phytohemagglutinin-stimulated non-tumor peripheral blood 
lymphocytes [24, 83]. These results thus suggest that these flavonoids might be used to 
increase the clinical efficacy of ATO. Similar to flavonoids, subcytotoxic concentrations of 
curcumin also has been demonstrated to stimulate ROS production and potentiate 
apoptosis induction by ATO in leukemia cell lines via deregulation of Akt phosphorylation 
[25].  
With these considerations in mind, a lot of preclinical and clinical trials have been carried 
out. For instance, we recently reported for the first time that 5-FU in combination with Vitex 
achieved an enhanced cytocidal effect on COLO 201 cells, but lesser cytotoxic effect on 
human PBMNC [9]. It has also been demonstrated that delphinidin induces apoptosis and 
inhibited NF-κB signaling in prostate tumor cells in vitro and in a human prostate tumor 
xenograft in nude mice in vivo [39]. Furthermore, twenty-five colon cancer patients without 
receiving prior therapy and surgery consumed 60 g/day (20 g/3x/day) of black raspberry 
powder daily for 2–4 weeks. Biopsies of normal-appearing and tumor tissues were taken 
from these patients before and after berry treatment. Intake of berries reduced proliferation 
rates and increased apoptosis in colon tumors but not in normal-appearing crypts [8]. On 
the other hand, supplementation of anthocyanins in the diet of cancer patients receiving 
chemotherapy did not result in increased inhibition of tumor development when compared 
to chemotherapy alone [84]. These conflicting findings suggest that a large scale of clinical 
trial is needed. 
A phase I clinical trial has shown that quercetin, another one of flavonoids, can be safely 
administered to patients with ovarian cancer or hepatoma by intravenous injection of bolus 
at a dose of 1400 mg/m2 [82]. Moreover, the evidence of antitumor activity was seen in the 
clinical trial based on sustained fall in serum CA 125 levels, which is proposed for the use as 
a surrogate marker of response [85]. Furthermore, similar to our previous report [9], CDF (a 
difluorinated analog of curcumin), alone or in combination with 5-FU and oxaliplatin, was 
more potent than curcumin alone in reducing the number of chemoresistant HCT-116 and 
HT-29 colon cancer cells expressing CD44 and CD166 stem cell-like markers [56]. 
Concomitantly, cell growth inhibition, apoptosis induction and disintegration of 
colonospheres in these colon cancer cells were also observed in the study [56]. Moreover, 
clinical trials have confirmed the safety and feasibility to use curcumin in combination 
therapy with current chemotherapeutic treatments [7]. More recent results from a phaseI/II 
study on 21 advanced pancreatic cancer patients with gemcitabine-based chemotherapy 
have indicated that the median overall survival time of the patients after a treatment with 
curcumin plus gemcitabine or gemcitabine/S-1 combination was 161 days and 1-year 
survival rate of 19% (95% confidence interval) [86]. Among eighteen evaluable patients, no 
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patients experienced a partial or complete response and five patients (28%) demonstrated 
stable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) [86].  
Although many encouraging results of in vitro and in vivo studies suggest polyphenolic 
compounds as a promising candidate for cancer therapy, either alone or in combination 
with current anticancer drugs, the therapeutic applications of these compounds in humans 
are limited by their high metabolic instability as well as poor absorption and bioavailability 
[1, 7, 8, 20, 87]. In this regard, the selective delivery of nanotechnology-based formulations 
of these polyphenolic compounds to tumors, alone or in combination with other anticancer 
drugs, has been of great interest [7, 26, 88]. For instance, pegylated liposomal quercetin was 
shown to significantly improve its solubility and bioavailability and be a potential applica-
tion in the treatment of tumor based on a study using CT26 (a mouse colorectal carcinoma 
cell line), LL/2 (Lewis lung cancer cell line) and H22 (a hepatoma cell line) xenograft mice 
[88]. Furthermore, diverse curcumin formulations have been developed with different nano-
technology consisting of its encapsulation or conjugation with nanoparticles, polymeric 
micelles or liposomes to improve its stability, bioavailability and specific and sustained 
delivery into cancer cells and, consequently, its anticarcinogenic effects [7]. In particular, the 
systemic administration of gemcitabine plus polymeric micelle-encapsulated curcumin 
formulation enhanced greater bioavailability in plasma and tissues as compared to that of 
free curcumin in xenograft models of human pancreatic cancer established in athymic mice 
[89]. In consequence, the combinatory administration efficiently block tumor growth and 
metastases in this animal model of pancreatic cancer. Furthermore, an inhibition of NF-κB 
and its targeted genes are implicated in the tumor growth inhibition [89]. Therefore, the use 
of nanotechnology-based formulations of polyphenolic compounds and their novel chemical 
analogs probably represents a potential alternative strategy of great clinical interest for 
overcoming the high metabolic instability and poor bioavailability of these compounds, 
which are among the principal factors limiting their therapeutic applications. 
4. Conclusion 
A striking global research on substances derived from natural products including 
polyphenolic compounds is being explored to understand the detailed mechanisms of their 
chemopreventive, antitumoral and chemosensibilizing activities against various types of 
aggressive and recurrent cancers. Besides the involvement of altered redox status in 
apoptosis induction triggered by these compounds, anti-inflammatory effects, anti-
angiogenesis, anti-invasiveness and induction of differentiation are well known to be 
implicated in their broad biological functions. It is worthy of note that flavonoids have 
been revealed to inhibit the function of ATP-binding cassette transporters such as 
multidrug resistance-associated proteins as well as P-glycoprotein [90], similar to our 
recent study [91]. On the other hand, a recent study demonstrated that berry anthocyanins, 
such as cyanidin-3-galactosidee, and cyanidin-3-glucoside as well as peonidin-3-glucosid, 
exhibit affinities for the efflux transporters breast cancer resistance protein (BCRP) and 
consequently may be actively transported out of intestinal tissues and endothelia [92]. 
However, the same report also demonstrated that some berry anthocyanins and 
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anthocyanidins, such as delphinidin, cyanidin and cyanidin-3-rutinoside, act as BCRP 
inhibitor, while some of them, such as malvidin, malvidin-3-galactoside and petunidin, 
exhibited bimodal activities serving as BCRP substrates and inhibitors at low 
concentrations and high concentrations, respectively [92]. These findings suggest that a 
variety of biological activities of anthocyanins and anthocyanidins may be attributed in 
part to their inhibitory effects on those drug transporters, paradoxically, may be abolished 
as a result of efflux through those transporters. These findings also raised a 
pharmacological and pharmaceutical concern about formulatability of the dietary 
constituent, and warn us against the casual use of herbs and/or other botanicals in cancer 
patient care. 
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